Clinical experience with romiplostim
Twenty patients with primary immune thrombocytopenia (ITP) received romiplastim as a second line therapy, and 3 patients with secondary thrombocytopenia as off-label. Romiplostim appeared effective in 85 % of patients with both persistent and chronic primary ITP. In patients with resistant and refra...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2014-07-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/10 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849689842280038400 |
|---|---|
| author | G. B. Kuchma L. K. Kozlova Ye. Ye. Kuznetsova S. B. Borisyuk |
| author_facet | G. B. Kuchma L. K. Kozlova Ye. Ye. Kuznetsova S. B. Borisyuk |
| author_sort | G. B. Kuchma |
| collection | DOAJ |
| description | Twenty patients with primary immune thrombocytopenia (ITP) received romiplastim as a second line therapy, and 3 patients with secondary thrombocytopenia as off-label. Romiplostim appeared effective in 85 % of patients with both persistent and chronic primary ITP. In patients with resistant and refractory ITP romiplostim response has not been registered, or it was lost. Achieving complete response to romiplostim therapy allowed its cancelation in 30 % of patients while maintaining the therapeutic effect; 15 % of patients switched to the 1 injection/biweekly in doses 4–5 mg/kg. Adverse events were observed in 21 % of patients and were temporary. With long-term use drug efficacy is not reduced, and the frequency of adverse events do not increase. Short course of romiplostim was successfully applied before surgical intervention for correction of thrombocytopenia in 3 patients with rheumatic diseases. |
| format | Article |
| id | doaj-art-cece2b9308584ed28b61eaa4e6e19000 |
| institution | DOAJ |
| issn | 1818-8346 2413-4023 |
| language | Russian |
| publishDate | 2014-07-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Онкогематология |
| spelling | doaj-art-cece2b9308584ed28b61eaa4e6e190002025-08-20T03:21:30ZrusABV-pressОнкогематология1818-83462413-40232014-07-0191424610.17650/1818-8346-2014-9-1-42-4625Clinical experience with romiplostimG. B. Kuchma0L. K. Kozlova1Ye. Ye. Kuznetsova2S. B. Borisyuk3ГБОУ ВПО «Оренбургская государственная медицинская академия» Минздрава РоссииГБОУ ВПО «Оренбургская государственная медицинская академия» Минздрава РоссииГБУЗ «Оренбургская областная клиническая больница»ГБУЗ «Оренбургская областная клиническая больница»Twenty patients with primary immune thrombocytopenia (ITP) received romiplastim as a second line therapy, and 3 patients with secondary thrombocytopenia as off-label. Romiplostim appeared effective in 85 % of patients with both persistent and chronic primary ITP. In patients with resistant and refractory ITP romiplostim response has not been registered, or it was lost. Achieving complete response to romiplostim therapy allowed its cancelation in 30 % of patients while maintaining the therapeutic effect; 15 % of patients switched to the 1 injection/biweekly in doses 4–5 mg/kg. Adverse events were observed in 21 % of patients and were temporary. With long-term use drug efficacy is not reduced, and the frequency of adverse events do not increase. Short course of romiplostim was successfully applied before surgical intervention for correction of thrombocytopenia in 3 patients with rheumatic diseases.https://oncohematology.abvpress.ru/ongm/article/view/10immune thrombocytopeniaromiplostimcomplete responseobjective responseabsence of a response |
| spellingShingle | G. B. Kuchma L. K. Kozlova Ye. Ye. Kuznetsova S. B. Borisyuk Clinical experience with romiplostim Онкогематология immune thrombocytopenia romiplostim complete response objective response absence of a response |
| title | Clinical experience with romiplostim |
| title_full | Clinical experience with romiplostim |
| title_fullStr | Clinical experience with romiplostim |
| title_full_unstemmed | Clinical experience with romiplostim |
| title_short | Clinical experience with romiplostim |
| title_sort | clinical experience with romiplostim |
| topic | immune thrombocytopenia romiplostim complete response objective response absence of a response |
| url | https://oncohematology.abvpress.ru/ongm/article/view/10 |
| work_keys_str_mv | AT gbkuchma clinicalexperiencewithromiplostim AT lkkozlova clinicalexperiencewithromiplostim AT yeyekuznetsova clinicalexperiencewithromiplostim AT sbborisyuk clinicalexperiencewithromiplostim |